Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 10 Results

Title
Intervention Indication Therapeutic Area Year Actions
Tafasitamab with lenalidomide as add-on therapy for previously treated follicular lymphoma or marginal zone lymphoma Lenalidomide (Revlimid) , Tafasitamab (MOR208; Monjuvi) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2023 View  |  Download
Lenalidomide in addition to R-CHOP chemotherapy for diffuse large B-cell lymphoma Lenalidomide (Revlimid) , R-CHOP Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2019 View  |  Download
Lenalidomide (Revlimid) in combination with rituximab for untreated follicular lymphoma Lenalidomide (Revlimid) , Rituximab (MabThera; Rituxan; RG 105) Follicular lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Lenalidomide (Revlimid) + rituximab for relapsed/refractory follicular lymphoma and marginal zone lymphoma Lenalidomide (Revlimid) , Rituximab (MabThera; Rituxan; RG 105) Follicular lymphoma , Marginal zone lymphoma (MZL) Haematological Cancer and Lymphomas 2017 View  |  Download
Isatuximab induction therapy with bortezomib, lenalidomide and dexamethasone for previously untreated multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2023 View  |  Download
Isatuximab in addition to bortezomib, lenalidomide and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Isatuximab (SAR650984; Sarclisa) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2021 View  |  Download
Daratumumab with bortezomib, lenalidomide and dexamethasone for previously untreated transplant eligible multiple myeloma Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Daratumumab in addition to bortezomib, lenalidomide and dexamethasone for multiple myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2020 View  |  Download
Daratumumab (Darzalex) with lenalidomide and dexamethasone for multiple myeloma – first line Daratumumab (Darzalex; JNJ-54767414) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Lenalidomide (Revlimid) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications